Health technologies for rare diseases: Does conventional HTA still apply?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 3, 2014, Pages 315-317

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

health technology; health technology assessment; multi criteria decision analysis; rare diseases

Indexed keywords

BUDGET; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; NATIONAL HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RARE DISEASE; REIMBURSEMENT; REVIEW; SOCIAL ASPECT; SOCIAL WORK; BIOMEDICAL TECHNOLOGY ASSESSMENT; DECISION SUPPORT SYSTEM; ECONOMICS; RARE DISEASES;

BIOMEDICAL TECHNOLOGY; DECISION SUPPORT TECHNIQUES; HUMANS; RARE DISEASES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84900828070     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.906903     Document Type: Review

References (13)

1. EUnetHTA. What is health technology assessment (HTA)?, 2014. Available from: www.eunethta.eu/about-us/faq#t287n73
2. Canadian Agency for Drugs and Technologies in Health. Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives. 2013. Available from: www.cadth.ca/media/pdf/ES0281- RareDiseaseDrugs-es-e.pdf
3. Drummond MF, Wilson DA, Kanavos P, et al. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007;23(1):36-42
4. Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ 2014; In press
5. Devlin N, Sussex J. Incorporating multiple criteria in HTA-methods and processes. Office of Health Economics, London, UK; 2011
6. Thokala P, Duenas A. Multiple criteria decision analysis for health technology assessment. Value Health 2012;15:1172-81
7. Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Eff Resour Alloc 2006;4(14)
8. Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 2012;7(1):74
9. Sussex J, Rollet P, Garau M, et al. Multi-criteria decision analysis to value orphan medicines. Office of Health Economics, London, UK. 2013
10. Hutton J, Rutten FFH, Van Hasselt P, et al. Economic relevance and validation procedure Orphan Medicinal Products. Europe-ExPro; 2014
11. AGNSS Advisory. Group for National Specialised Services. NHS Specialised Services. 2014. Available from: www.specialisedservices.nhs.uk/info/agnss
12. Shire. Multi-criteria decision analysis in Health Technology Assessments of orphan drugs. 2012. Available from: www.shire.com/shireplc/dlibrary/ documents/DecisionAnalysisinHTAOrphanDrugs.pdf
13. National Institute for Health and Care Excellence. Interim. process and methods of the highly specialised technologies programme. 2013. Available from: www.nice.org.uk/media/DE4/9A/HSTCombinedInterimProcessMethods.pdf